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Certainty of genuine treatment increases
drug responses among intellectually
disabled patients
ABSTRACT
Objective: To determine the placebo component of treatment responses in patients with intellec-
tual disability (ID).
Methods: A statistical meta-analysis comparing bias-corrected effect sizes (Hedges g) of drug
responses in open-label vs placebo-controlled clinical trials was performed, as these trial types
represent different certainty of receiving genuine treatment (100% vs 50%). Studies in fragile X,
Down, Prader-Willi, and Williams syndrome published before June 2015 were considered.
Results: Seventeen open-label trials (n 5 261, 65% male; mean age 23.6 years; mean trial
duration 38 weeks) and 22 placebo-controlled trials (n 5 721, 62% male; mean age 17.1 years;
mean trial duration 35 weeks) were included. The overall effect size from pre to post treatment in
open-label studies was g5 0.602 (p5 0.001). The effect of trial type was statistically significant
(p 5 0.001), and revealed higher effect sizes in studies with 100% likelihood of getting active
drug, compared to both the drug and placebo arm of placebo-controlled trials. We thus provide
evidence for genuine placebo effects, not explainable by natural history or regression toward the
mean, among patients with ID.
Conclusions: Our data suggest that clinical trials in patients with severe cognitive deficits are
influenced by the certainty of receiving genuine medication, and open-label design should thus
not be used to evaluate the effect of pharmacologic treatments in ID, as the results will be biased
by an enhanced placebo component. Neurology® 2017;88:1912–1918
GLOSSARY
DSM-V 5 Diagnostic and Statistical Manual of Mental Disorders, 5th edition; ID 5 intellectual disability.
In any pharmacologic treatment, contextual and cognitive factors contribute to the therapeutic
response, such as patients’ treatment expectations and knowledge about the treatment.1 These
factors, referred to as nonspecific treatment mechanisms, are active ingredients in placebo
responses.2 To date, little is known about the contribution of nonspecific treatment effects in
trials for patients with severe cognitive deficits.
Intellectual disability (ID) is defined by impaired intellectual functions, such as reasoning,
abstract thinking, and learning from experience. ID is confirmed by intelligence testing (IQ
,70), combined with assessments of mental abilities and adaptive functioning and evidence
that the observed limitations were manifested during the developmental period (DSM-V).3
A recent meta-analysis showed that patients with genetically determined ID display signifi-
cant improvements in the placebo arm in randomized controlled trials, both on subjective
and objective outcomes.4 Yet few studies included a no-treatment control group, and the
placebo response (improvement in the placebo arm) could thus not be separated from a true
placebo effect, which controls for natural history, being in a trial, and regression to the mean. In
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order to determine the placebo effect, which
rests on treatment expectations,2 studies in
other patient populations have developed
a method where drug responses in placebo-
controlled trials are compared with those in
open-label trials, as they represent 50% vs
100% certainty of receiving active drug.5–7
We assessed the placebo component in ID
clinical trials by performing a meta-analysis
comparing drug responses in open-label vs
placebo-controlled trials. Studies were
restricted to genetically determined ID, and
the statistical analyses were matched for drug
type, so that placebo-controlled and open-
label trials compared the same drugs.
METHODS Data. We followed the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses guidelines for re-
porting meta-analysis results, and data were obtained from
MEDLINE/PubMed and PsycINFO, based on searches for all
randomized, placebo-controlled (or open-label), pharmacologic
clinical trials in patients with genetically determined ID due to
fragile X, Down, Prader-Willi, or Williams syndrome, published
before June 2015.
Study selection. The inclusion criteria for this meta-analysis
were open-label (or randomized placebo-controlled) trials in pa-
tients with fragile X, Down, Prader-Willi, or Williams syndrome,
of any age, from any country, reported in the English language. In
line with our previous ID meta-analysis,4 studies were excluded if
(1) outcomes did not evaluate cognitive–developmental functions
or (2) the treatment targeted a peripheral comorbidity rather than
core symptoms of ID. Consolidated Standards of Reporting
Trials guidelines were employed to ensure adequate quality of the
studies included in this meta-analysis (figure 1).
Data extraction and quality assessment. Exclusion criteria
were (1) studies that failed to report an inference test or enough
information to compute an effect size, (2) studies with fewer than
5 patients, (3) studies that did not provide separate reports for
drug/placebo (applicable for placebo-controlled trials), (4) not
a randomized trial (applicable for placebo-controlled trials), (5)
only treatment results from healthy controls reported. Data
extraction was performed independently by 2 reviewers. Dis-
crepancies were adjusted in reviewer meetings and confirmed
with a third reviewer.
We checked for overlap in participants between studies from
the same authors. Based on the patient description including
mean age, age range, and date of inclusion, it was possible to rule
out the overlap in participants between studies by Erickson,
Heller, and Kishnani. More precisely, the mean age and age range
did not overlap, especially considering that in all these studies
from the same authors, the most recent ones were performed in
younger children. In the studies by Berry-Kravis, the majority
of patients were not included in both studies. There was some
doubt in less than 15% of the patients. It was not possible to rule
out some overlap in participants in the studies by Torrioli and
Prasher.
Statistical analysis. Treatment response was defined as the dif-
ference in outcome measures from pre to post treatment within
each treatment arm. Calculation of effect size was performed
by means of bias-corrected standardized mean differences
Figure 1 Flow chart for the open-label drug trials included in the meta-analysis
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Table 1 Open-label and placebo-controlled studies
Study Year Diagnosis No. of patients Age, y, mean Male, % Study design Trial duration, wk Drug
18a 2003 DS 6 29 83 Open-label 24 AChEi
19a 2010 DS 10 16 80 Open-label 20 AChEi
20a 2003 DS 6 51 b Open-label 80 AChEi
21a 2005 DS 17 53 b Open-label 24 AChEi
22a 2007 DS 7 10 14 Open-label 16 AChEi
23 2004 PWS 8 28 44 Open-label 8 Antiepileptic
24 2010 FXS 8 11 100 Open-label 26 Antiepileptic
25 2008 DS 23 8 87 Open-label 14 Antipsychotic
26 2000 PWS 7 19 71 Open-label 37 Antipsychotic
27a 2013 FXS 12 12 83 Open-label 10 GABA agonist
28a 2005 PWS 18 26 53 Open-label 52 GH
29a 2008 PWS 15 2 47 Open-label 52 GH
30a 2012 PWS 48 7 42 Open-label 208 GH
31a 2014 PWS 35 15 34 Open-label 12 N-acetylcysteine
32a 2009 FXS 6 18 b Open-label 35 NMDA antagonist
33 2014 FXS 16 18 88 Open-label 12 Statin
34a 2010 FXS 19 18 90 Open-label 8 Tetracycline
35a 2003 DS 9 30 58 Placebo-controlled 12 AChEi
36a 2009 DS 56 24 63 Placebo-controlled 12 AChEi
37a 2010 DS 62 13 52 Placebo-controlled 10 AChEi
38a 2011 DS 11 47 0 Placebo-controlled 24 AChEi
39a 2002 DS 14 53 50 Placebo-controlled 24 AChEi
40a 2013 FXS 10 10 100 Placebo-controlled 12 AChEi
e-1 2006 FXS 24 31 78 Placebo-controlled 4 Ampakine
e-2 1990 PWS 15 14 47 Placebo-controlled 6 Anorexic
e-3a 2012 FXS 56 16 87 Placebo-controlled 4 GABA agonist
e-4a 2003 PWS 12 9 50 Placebo-controlled 26 GH
e-5a 2008 FX 24 9 100 Placebo-controlled 52 L-acetylcarnitine
e-6a 2012 DS 18 23 37 Placebo-controlled 16 NMDA antagonist
e-7a 2012 DS 72 52 57 Placebo-controlled 52 NMDA antagonist
e-8a 2013 FXS 50 9 85 Placebo-controlled 13 Tetracycline
e-9 2005 DS 90 0 55 Placebo-controlled 104 Thyroxine
e-10 2010 DS 43 1 53 Placebo-controlled 52 Vitaminsc
e-11 2008 DS 106 0 57 Placebo-controlled 78 Vitaminsc
e-12 1986 FXS 25 16 100 Placebo-controlled 26 Vitaminsc
e-13 1983 DS 10 11 50 Placebo-controlled 35 Vitaminsc
e-14 1980 DS 69 0 56 Placebo-controlled 156 Vitaminsc
e-15 1984 DS 28 11 71 Placebo-controlled 35 Vitaminsc
e-16 1983 DS 24 12 66 Placebo-controlled 17 Vitaminsc
Abbreviations: AChEi 5 acetylcholinesterase inhibitor; DS 5 Down syndrome; FXS 5 fragile X syndrome; GABA 5 g-aminobutyric acid; GH 5 growth
hormone; PWS 5 Prader-Willi syndrome.
N-acetylcysteine/L-acetylcarnitine were combined into one category called LAC/NAC. References e-1–e-16 are available at Neurology.org.
a Studies that were included in the matched comparison between drug effects in open-label (k 5 12) vs placebo-controlled (k 5 12) studies (drug types
represented in both open-label and placebo-controlled studies).
bNo information given.
c Studies using folic acid alone or a combination of vitamins, minerals, or antioxidants.
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(Hedges g) using Comprehensive Meta-Analysis version 3.0
(meta-analysis.com). In order to adjust for heterogeneity in the
included data, all analyses were performed using random-effects
instead of fixed-effects models. In studies with multiple outcome
measures, a combined within-study outcome was computed as
a synthetic effect size (with a variance that takes account of the
correlation among the different outcomes). This approach cor-
rects for the problem of more weight being assigned to studies
with more outcomes.8 For a complete list of all outcomes, listed
per study, see table e-1 at Neurology.org.
An overall meta-analysis was performed to assess the effect size
of pre-post treatment within the open-label trials (for a correspond-
ing meta-analysis of the placebo-controlled studies, see our previous
report4). In order to compare the effect size of open-label and
placebo-controlled trials, studies were matched on drug category.
The only criteria for matching studies was that a drug category must
be represented in both open-label and placebo-controlled trials in
order to be included. Hence, the principle was to include all studies
from each eligible drug category, and we did not exclude any studies
based on other criteria. A wide range of treatments were represented
(including vitamins, g-aminobutyric acid agonists, and statins); for
a full list, see table e-2. Six different drug categories were repre-
sented both in open-label and placebo-controlled studies and were
thus used for the comparison between open-label and placebo-
controlled studies. Twelve open-label studies and 12 placebo-
controlled studies were included in the matched comparison (even
if there was no requirement to end up with the same number of
studies) (table 1). The overall effect was assessed using a univariate
analysis of variance, using trial duration (weeks) as covariate, and
Sidak correction for multiple comparisons was applied to the pair-
wise comparisons.
RESULTS Overall meta-analysis: open-label. Seventeen
open-label trials met the inclusion criteria,
comprising a total of 261 patients. The mean dura-
tion of studies was 38 weeks (SD 48, range 8–208
weeks). Sixty-five percent of the participants were
male, and the mean age was 23.6 years (SD 17.5,
range 2–53) (table 1). Three of the 17 open-label
trials, representing 29 (11.1%) participants, did not
report participant sex distribution. We initially
identified 13 open-label studies with Williams
syndrome but none of them was eligible: fewer than 5
patients in the trial (12 cases) and not evaluating
cognitive developmental functions (1 case).
The pre-post analysis of outcomes in the open-
label trials showed a significant treatment response
(g 5 0.602, SE 5 0.116, p , 0.001; figure 2). In
line with our previous reports of ID placebo responses
and trial duration,4 we found no significant correla-
tion between study effect size and length of open-
label clinical trials (r5 0.066, p5 0.802), indicating
that long and short trials had comparable treatment
results.
Overall meta-analysis: Placebo-controlled. Twenty-two
placebo-controlled studies met the inclusion criteria,
comprising 828 patients in the drug arm and 721 in
the placebo arm. The mean duration of studies was
35 weeks (SD 37, range 4–156 weeks). Sixty-two
percent of the participants were male, and the mean
age in the drug arm was 17.8 years (SD 16, range 0–
53) and 17.1 years (SD 15.6, range 0–55) in the
placebo arm.
Figure 2 Forest plot of treatment responses in open-label intellectual disability (ID) drug trials
A significant improvement from pre to post treatment was seen across all studies (p , 0.001). If studies included more than one outcome measure they
were combined into one value. A random-effects model was used to calculate significance.
Neurology 88 May 16, 2017 1915
As previously reported by our group,4 a pre-post
analysis of outcomes in placebo-controlled trials (k5
22) showed significant treatment responses, both in
the drug arm (g 5 0.678, SE 5 0.171, p , 0.001)
and the placebo arm (g 5 0.468, SE 5 0.150, p ,
0.005).4
Open-label vs placebo-controlled trials. The effect of
trial type on treatment outcomes was determined by
comparing effect sizes between drug-matched open-
label (k 5 12) and placebo-controlled (k 5 12) trials
(table 1), comprising a total of 199 patients (open-
label) and 394 patients (placebo-controlled). The
effect of trial type was statistically significant (F2,325
5.7, p 5 0.008, h2 5 0.263), and revealed higher
effect sizes in studies with 100% likelihood of getting
active drug (open-label, mean g 5 0.65, SD 5 0.41)
compared to the drug arm (p 5 0.043) (mean g 5
0.31, SD 5 0.38) and placebo arm (p 5 0.009)
(mean g 5 0.21, SD 5 0.34) in placebo-controlled
studies (figure 3). The study effect sizes were not
affected by trial duration in any of the 3 groups: open-
label drug (r 5 0.34, p 5 0.287), placebo-controlled
drug (r 5 0.15, p 5 0.645), or placebo-controlled
placebo (r 5 0.243, p 5 0.447), indicating that ID
treatment responses were unaffected by differences in
trial length.
DISCUSSION Our comparison between drug effects
in open-label and placebo-controlled studies validate
that treatment expectations play a role in treatment of
ID, in spite of severe cognitive deficits. In open-label
studies, patients (as well as their doctors and families)
are assured that the allocated treatment contains an
active drug, and thus the contribution of positive
treatment expectations is likely to be high. In
placebo-controlled trials, however, there is generally
a 50% chance of receiving an active drug. The cer-
tainty of getting active medication in placebo-
controlled trials is thus lower, and may provide less
positive expectations of improvement. The effect of
certainty in drug trials is previously reported among
individuals with intact cognitive functions,5–7,9 and
evidence suggests that certainty of receiving the real
drug maximizes patients’ treatment expectations,
leading to higher treatment responses.10 Here we
demonstrate, for the first time, that patients with
severe cognitive deficits are susceptible to the different
treatment contexts of open-label and placebo-
controlled drug trials, similar to the effects seen in
non-ID patients.6,7Open-label drug trials in ID pa-
tients are therefore biased by the certainty of receiving
genuine medication, and should not be used to study
pharmacologic effects in ID, as the results will be
misleading. Novel therapies for ID that target the
underlying pathophysiology are currently being
developed, for example for Down syndrome and
fragile X syndrome.11 New promising results can lead
to a general increase of treatment expectancy among
patients’ families, which may enhance the bias (as
seen in secretin trials for children with autism12,13) if
treatments are not tested in properly blinded placebo-
controlled designs. Even if open-label drug trials will
not be able to separate the pharmacologic effect from
the placebo component of a given treatment, open-
label trials may be used for the purpose of assessing
side effects. Nonetheless, research in non-ID patients
shows that side effects are also shaped by expectations
though so-called nocebo effects,14 and it is important
to recognize the possibility that information about
side effects (written/oral) may affect the occurrence of
adverse effects also in ID patients.
In response to the prevalent notion that ID pa-
tients are less susceptible to treatment expectancies,
we previously performed a meta-analysis where we
were able to demonstrate that patients with geneti-
cally determined ID display placebo responses in
placebo-controlled clinical trials.4 Yet our previous
meta-analysis did not compare placebo responses to
a no-treatment control, and we could therefore not
decidedly link the pre to post improvements to pla-
cebo mechanisms (even if natural remission of genet-
ically determined ID would be unlikely). In the
present analysis, we employed a balanced design that
Figure 3 Drug response from pre to post
treatment in drug-matched open-label
and placebo-controlled trials
There was a significant difference between study effect sizes
between drug-matched open-label (k5 12), placebo-controlled
drug (k 5 12), and placebo-controlled placebo (k 5 12) treat-
mentgroups.Theoverall effectwasassessedusingaunivariate
analysis of variance and Sidak correction for multiple compar-
isons was applied to the pairwise comparisons. *Significant at
p , 0.01; **significant at p , 0.05.
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allowed for interpretation of the role of treatment
expectations between open-label and placebo-
controlled drug trials. Patients with ID thereby
demonstrated genuine placebo effects, which are
not explained by spontaneous remission or regression
to the mean.
There are several possible mechanisms involved in
shaping treatment expectations and placebo effects,
including implicit and explicit learning.15 In addition
to verbal information about the benefits of a drug
(requiring cognitive learning abilities), treatment cues
may be implicitly embedded in the patient–clinician
interaction and clinical environment.16 In patients
with ID, it is likely that the implicit social influence of
placebo by proxy17 plays a role, which describes the
indirect influence of treatment expectations among
clinicians and close relatives, and has been mentioned
apropos of placebo effects in young children. In brief,
placebo by proxy refers to an alteration in the
patient’s psychosocial context that may promote
placebo effects in a way that is not strictly a learning
phenomenon, yet it may have the same profound
influence on patients’ response, for example through
caregiver’s altered behavior towards the patient. Even
if we studied the effects of active drugs (and not
placebos) in this study, the placebo by proxy phe-
nomenon is highly relevant for understanding the
placebo component of genuine treatment outcomes.
Here, the effect may be described as an expectancy by
proxy effect on clinical outcomes, reflecting the ex-
pectations of surrounding parents, caretakers, and
clinicians.
Limitations to our study include the inability to
control for the possibility that treatment responses
rated subjectively by parents, teachers, or caregivers
were biased by raters’ knowledge of trial type, despite
no or little effect on patients’ actual behavior. We
have previously been able to reject the notion that
subjectively rated outcomes have larger placebo ef-
fects compared to objectively measured outcomes in
ID patients,4 and predict that the same is true in the
present study. In our previous study, we found that
the relatively small number of studies (k 5 22) led to
differences in effect size if outliers were removed. We
also demonstrated significant differences in treatment
responses based on which drug was used in the trial,
both in the drug arm and the placebo arm.4 In order
to address drug heterogeneity in the present study, we
used a drug-matched approach when analyzing the
effect of trial type. Yet this reduced the sample size
and led to apparent differences in effect size for the
overall vs subgroup data. Another limitation is the
restriction to include studies that measure treatment
effects on core ID symptoms. In the future, it would
be valuable to assess the placebo component of treat-
ment for somatic symptoms in patients with ID.
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